ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Eurofins CDMO Alphora says its pilot-scale biologic drug development facility in Mississauga, Ontario, is ready for use. The 300 m2 facility is intended to serve drug companies with upstream and downstream development, process design, analytical development, cell-based assays, and preclinical or Phase 1 trial supply. It marks the entry of Alphora, traditionally a custom manufacturer of small molecules, into the business of making monoclonal antibodies and other mammalian-based therapeutic proteins for drug industry customers.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X